Automated qNMR data processing and analysis in the behind the scenes of fragment-based drug discovery

CASE STUDY

Bringing new drugs into the market is a long, complex process that often requires several years of investigation and considerable human, technological, and economic resources. In the labs of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, a Fragment-Based Drug Discovery (FBDD) program has been established for screening and identifying lead compounds with potential therapeutic effects that may serve as starting points for the development of potent drug candidates.

"Back in 2017, only one project is using qNMR for solubility; since we implemented Mnova automated qNMR in 2018, all our projects are now using the method"

Maggie Liu
Expert NMR Spectroscopist in the structural chemistry team - Institute of Cancer Research (ICR)